Professor Lars A Carlson is currently Emeritus Research Professor at the Karolinska Institutet and Director of the Lipid and Hypertension Clinic at Sophiahemmet, Stockholm, Sweden. He qualified in medicine at the Karolinska Institutet, and later obtained his PhD there. His clinical training was undertaken at the Department of Internal Medicine, Karolinska Hospital. He became the first Swedish Professor of Geriatric Medicine in Uppsala and created the Department of Geriatric Medicine at Uppsala University. This was followed by positions at the Karolinska Institutet as Professor of Internal Medicine and at the Department of Internal Medicine, Karolinska Hospital as a Consultant Physician. At the same time he was Director of the King Gustaf V Research Institute, Karolinska Institutet. He has also been a Visiting Professor at the Royal Postgraduate Medical School, Hammersmith Hospital, London, and the University Department of Medicine, Hopital Cantonal, Geneva, Switzerland. Professor Carlson has been the President of the European Society for Clinical Investigation and the European Atherosclerosis Society. He has been the editor of the journal Atherosclerosis and has published some 500 scientific articles. For 20 years he has been a member of the Nobel Assembly, Karolinska Institutet. His main research interests include clinical lipidology and atherosclerosis. He received the prestigious Oscar Minkowski Prize of the European Diabetes Society and several other national and international awards for scientific achievements.

• Part one Lipid testing.- 1 Atherosclerosis and clinical atherosclerosis.- 2 From cholesterol to lipoproteins and apolipoproteins.- 3 Lipid testing.- 4 Lipid profiles.- 5 Lipid testing and prediction of coronary heart disease.- 6 Lipid risk factors in prediction of coronary heart disease – is any one factor best.- Part two Lipid management.- 7 Goals of lipid management.- 8 Cholesterol lowering and prevention of CHD.- 9 Cholesterol goals in current guidelines.- 10 Lipid management in clinical practice.- 11 Drugs for lipid management.- 12 Diabetic dyslipidaemia.- 13 LDL apheresis.- 14 Lipid modifying agents under development.